+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mannkind Corporation - logo

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

From
Nontuberculous Mycobacteria (Ntm) Infections - Pipeline Insight, 2021 - Product Thumbnail Image

Nontuberculous Mycobacteria (Ntm) Infections - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 60 Pages
  • Global
From
Migraine - Pipeline Review, H2 2020 - Product Thumbnail Image

Migraine - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 342 Pages
  • Global
From
From
From
From
Loading Indicator